Research programme: anti-infective monoclonal antibodies - AIMM Therapeutics

Drug Profile

Research programme: anti-infective monoclonal antibodies - AIMM Therapeutics

Alternative Names: Anti Staph A mAb rF1; Bispecific influenza virus antibody; Clostridium difficile antibody; Cytomegalovirus antibody; Hepatitis C virus antibody; Parechovirus antibody; rF1

Latest Information Update: 08 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AIMM Therapeutics
  • Developer AIMM Therapeutics; Genentech
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Clostridium infections; Cytomegalovirus infections; Hepatitis C; Influenza virus infections; Picornavirus infections

Highest Development Phases

  • Preclinical Influenza virus infections; Methicillin-resistant Staphylococcus aureus infections
  • Research Clostridium infections; Cytomegalovirus infections; Hepatitis C
  • No development reported Picornavirus infections

Most Recent Events

  • 08 May 2014 This programme is still in active development
  • 08 May 2014 Antibodies against the following targets: group 1 and group 2 HA antigens of influenza virus (bispecific antibody), cytomegalovirus, hepatitis C virus, parechovirus and Clostridium difficile are still available for partnering.
  • 08 May 2014 No development reported for Picornavirus infections in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top